2anm: Difference between revisions

Revision as of 12:16, 29 July 2008

This article has been automatically seeded. Changes to this page should pertain to the PDB entry only and not to the protein or biomolecule in general.

File:2anm.png

Template:STRUCTURE 2anm

Ternary complex of an orally active thrombin inhibitor with human thrombin and a c-terminal hirudin derived exo-sit inhibitorTernary complex of an orally active thrombin inhibitor with human thrombin and a c-terminal hirudin derived exo-sit inhibitor

Template:ABSTRACT PUBMED 16460939

About this StructureAbout this Structure

2ANM is a Protein complex structure of sequences from Homo sapiens. Full crystallographic information is available from OCA.

ReferenceReference

Orally active thrombin inhibitors. Part 2: optimization of the P2-moiety., Lange UE, Baucke D, Hornberger W, Mack H, Seitz W, Hoffken HW, Bioorg Med Chem Lett. 2006 May 15;16(10):2648-53. Epub 2006 Feb 3. PMID:16460939

Page seeded by OCA on Tue Jul 29 12:16:26 2008

Proteopedia Page Contributors and Editors (what is this?)Proteopedia Page Contributors and Editors (what is this?)

OCA

@@ Line 1: / Line 1: @@
-[[Image:2anm.gif|left|200px]]
+{{Seed}}
+[[Image:2anm.png|left|200px]]
 <!--
@@ Line 9: / Line 10: @@
 {{STRUCTURE_2anm|  PDB=2anm  |  SCENE=  }}
-'''Ternary complex of an orally active thrombin inhibitor with human thrombin and a c-terminal hirudin derived exo-sit inhibitor'''
+===Ternary complex of an orally active thrombin inhibitor with human thrombin and a c-terminal hirudin derived exo-sit inhibitor===
-==Overview==
+<!--
-Synthesis and SAR of orally active thrombin inhibitors of the d-Phe-Pro-Arg type with focus on the P2-moiety are described. The unexpected increase in in vitro potency, oral bioavailability, and in vivo activity of inhibitors with dehydroproline as P2-isostere is discussed. Over a period of 24h the antithrombin activity of the most active inhibitors with IC(50)s in the nanomolar range was determined in dogs demonstrating high thrombin inhibitory activity in plasma and an appropriate duration of action after oral administration.
+The line below this paragraph, {{ABSTRACT_PUBMED_16460939}}, adds the Publication Abstract to the page
+(as it appears on PubMed at http://www.pubmed.gov), where 16460939 is the PubMed ID number.
+-->
+{{ABSTRACT_PUBMED_16460939}}
 ==About this Structure==
@@ Line 30: / Line 34: @@
 [[Category: Seitz, W.]]
 [[Category: Blood clotting]]
-''Page seeded by [http://oca.weizmann.ac.il/oca OCA ] on Sat May  3 19:15:26 2008''
+''Page seeded by [http://oca.weizmann.ac.il/oca OCA ] on Tue Jul 29 12:16:26 2008''